{{위키데이터 속성 추적}}
{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 477316140
| image = Agomelatine formula.svg
| alt = 
| image2 = Agomelatine-3D-ball.png
| alt2 =

<!--Clinical data-->
| tradename =  Melitor, Thymanax, Valdoxan, others
| Drugs.com = {{drugs.com|international|agomelatine}}
| licence_EU = yes
| pregnancy_AU = B1
| routes_of_administration = 구강 투여
| ATC_prefix = N06
| ATC_suffix = AX22

| legal_AU = S4
| legal_AU_comment =<ref name = "AU PI"/>
| legal_UK = POM
| legal_UK_comment =<ref>{{웹 인용| title=Valdoxan 25 mg film-coated tablets - Summary of Product Characteristics (SmPC) | website=(emc) | date=13 July 2020 | url=https://www.medicines.org.uk/emc/product/6564/smpc | access-date=14 January 2021}}</ref>
| legal_EU = Rx-only
| legal_EU_comment =<ref>{{웹 인용| title=Thymanax EPAR | website=[[European Medicines Agency]] (EMA) | url=https://www.ema.europa.eu/en/medicines/human/EPAR/thymanax | access-date=14 January 2021}}</ref><ref>{{웹 인용| title=Valdoxan EPAR | website=[[European Medicines Agency]] (EMA) | url=https://www.ema.europa.eu/en/medicines/human/EPAR/valdoxan | access-date=14 January 2021}}</ref>

<!--Pharmacokinetic data-->
| protein_bound = 95%<ref name = "AU PI"/>
| bioavailability = 1%<ref name="AU PI">{{웹 인용|title=Valdoxan Product Information | url = https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-PI-07273-3 |work=TGA eBusiness Services|publisher=Servier Laboratories Pty Ltd.|access-date=2013-10-14|format=PDF|date=2013-09-23|url-status=live|archive-url=https://web.archive.org/web/20170324132859/https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-PI-07273-3|archive-date=2017-03-24}}</ref>
| metabolism = [[Liver]] (90% [[CYP1A2]] and 10% [[CYP2C9]])<ref name = "AU PI"/>
| elimination_half-life = 1–2시간<ref name = "AU PI"/>
| excretion =  [[Kidney]] (80%, mostly as metabolites)<ref name = "AU PI"/>

<!--Identifiers-->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 138112-76-2
| PubChem = 82148
| IUPHAR_ligand = 198
| DrugBank_Ref = {{drugbankcite|changed|drugbank}}
| DrugBank = DB06594
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 74141
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 137R1N49AD
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D02578
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 10878
| synonyms = AGO-178; AGO178C; S-20098; S-20098-F55

<!--Chemical data-->
| IUPAC_name = ''N''-[2-(7-methoxynaphthalen-1-yl)ethyl]acetamide
| C=15 | H=17 | N=1 | O=2
| SMILES = O=C(NCCc1c2c(ccc1)ccc(OC)c2)C
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C15H17NO2/c1-11(17)16-9-8-13-5-3-4-12-6-7-14(18-2)10-15(12)13/h3-7,10H,8-9H2,1-2H3,(H,16,17)
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = YJYPHIXNFHFHND-UHFFFAOYSA-N
}}
'''아고멜라틴'''(Agomelatine, 상품명으로 '아고틴' 등이 사용된다)은 항우울제의 하나이다. 대한민국에서는 [[환인제약]]에서 수입 및 판매하고 있다.

== 작용 기전 ==
멜라토닌과 세로토닌 수용체에 작용을 하여, 우울증 상태를 개선하는데 상호 보완적이고 조화롭게 작용하여 불안 장애 완화는 물론, 수면의 질 및 낮 시간의 활동 기능을 개선하는데 효과적인 항우울제이므로, 성기능 장애 등 부작용이 현저히 낮다.

== 합성 ==
[[파일:Agomelatine-synthesis.svg|섬네일|가운데|700px|Agomelatine-synthesis:<ref>{{cite patent |country= EP |number= 447285 |status= application |title= Naphthalene derivatives, procedure for their preparation and pharmaceutical compositions containing them.|pubdate= 1991-09-18 |gdate= |fdate= |pridate= |inventor= Andrieux J, Houssin R, Yous S, Guardiola B, Lesieur D |assign1= Adir }}</ref><ref>{{cite patent |country= US |number= 5225442 |status= granted |title= Compounds having a naphthalene structure  |pubdate= |gdate= 6 July 1993 |fdate= |pridate= |inventor= Andrieux J, Houssin R, Yous S, Guardiola B, Lesieur D |assign1= Adir }}</ref> and structure-activity studies:<ref>{{저널 인용| vauthors = Yous S, Andrieux J, Howell HE, Morgan PJ, Renard P, Pfeiffer B, Lesieur D, Guardiola-Lemaitre B | title = Novel naphthalenic ligands with high affinity for the melatonin receptor | journal = Journal of Medicinal Chemistry | volume = 35 | issue = 8 | pages = 1484–6 | date = April 1992 | pmid = 1315395 | doi = 10.1021/jm00086a018 }}</ref><ref>{{저널 인용| vauthors = Depreux P, Lesieur D, Mansour HA, Morgan P, Howell HE, Renard P, Caignard DH, Pfeiffer B, Delagrange P, Guardiola B | title = Synthesis and structure-activity relationships of novel naphthalenic and bioisosteric related amidic derivatives as melatonin receptor ligands | journal = Journal of Medicinal Chemistry | volume = 37 | issue = 20 | pages = 3231–9 | date = September 1994 | pmid = 7932550 | doi = 10.1021/jm00046a006 }}</ref>]]

== 각주 ==
{{각주}}

{{항우울제}}
{{전거 통제}}
{{토막글|의학}}

[[분류:항우울제]]
[[분류:나프톨 에터]]